Literature DB >> 30846324

Low muscle mass is associated with early termination of chemotherapy related to toxicity in patients with head and neck cancer.

Martine J Sealy1, Tanadech Dechaphunkul2, Cees P van der Schans3, Wim P Krijnen4, Jan L N Roodenburg5, John Walker6, Harriët Jager-Wittenaar7, Vickie E Baracos8.   

Abstract

BACKGROUND & AIMS: We studied whether low pre-treatment muscle mass, measured with CT at thoracic (T4) or lumbar level (L3) associates with early termination of chemotherapy related to toxicity in head and neck cancer (HNC) patients.
METHODS: This was a retrospective chart and image review. Adult HNC patients treated with (surgery and) platinum-based chemo-radiotherapy were included if a pre-treatment CT scan at T4 or L3 level was available. Muscle mass was evaluated by assessment of skeletal muscle index (SMI; cm2/m2). T4 and L3 SMI measurements were corrected for deviation from their respective means and were merged into one score for SMI difference (cm2/m2). All cases were assessed for presence of toxicity-related unplanned early termination of chemotherapy ('early termination'). Univariate and multivariate logistic regression models were used to investigate associations between pooled SMI and early termination.
RESULTS: 213 patients (age: 57.9 ± 10.3 y, male: 77%, T4 image: 45%) were included. A significant association between SMI as a continuous variable and early termination was found, both in the univariate analysis (p = 0.007, OR = 0.96 [0.94-0.99]) and the multivariate analysis (p = 0.021, OR 0.96 [0.92-0.99]). The multivariate models identified potential associations with type of chemotherapy, presence of co-morbidity, a combination of (former) smoking and alcohol consumption, and sex.
CONCLUSION: Lower muscle mass was robustly associated with higher odds of early termination of chemotherapy in HNC patients. Further prospective studies are required to tailor the care for patients with low muscle mass and to avoid early termination of chemotherapy.
Copyright © 2019 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Body composition; Chemotherapy; Computed tomography; Head and neck cancer; Muscle mass; Treatment toxicity

Year:  2019        PMID: 30846324     DOI: 10.1016/j.clnu.2019.02.029

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  14 in total

Review 1.  The Obesity Paradox in Cancer: Epidemiologic Insights and Perspectives.

Authors:  Dong Hoon Lee; Edward L Giovannucci
Journal:  Curr Nutr Rep       Date:  2019-09

2.  Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer.

Authors:  Najiba Chargi; Fereshta Bashiri; Anne W Wendrich; Ernst J Smid; Pim A de Jong; Alwin D R Huitema; Lot A Devriese; Remco de Bree
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-01-17       Impact factor: 2.503

Review 3.  The Impact of Immune Cells on the Skeletal Muscle Microenvironment During Cancer Cachexia.

Authors:  Brandon N VanderVeen; E Angela Murphy; James A Carson
Journal:  Front Physiol       Date:  2020-08-31       Impact factor: 4.566

4.  The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin.

Authors:  Sandra I Bril; Abrahim Al-Mamgani; Najiba Chargi; Peter Remeijer; Lot A Devriese; Jan Paul de Boer; Remco de Bree
Journal:  Head Neck       Date:  2021-10-29       Impact factor: 3.821

5.  Meeting Minimum ESPEN Energy Recommendations Is Not Enough to Maintain Muscle Mass in Head and Neck Cancer Patients.

Authors:  Benjamin McCurdy; Sara Nejatinamini; Brock J Debenham; Mirey Álvarez-Camacho; Catherine Kubrak; Wendy V Wismer; Vera C Mazurak
Journal:  Nutrients       Date:  2019-11-12       Impact factor: 5.717

Review 6.  Inflammation and Skeletal Muscle Wasting During Cachexia.

Authors:  Justine M Webster; Laura J A P Kempen; Rowan S Hardy; Ramon C J Langen
Journal:  Front Physiol       Date:  2020-11-19       Impact factor: 4.566

7.  The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis.

Authors:  Laura F J Huiskamp; Najiba Chargi; Lot A Devriese; Anne M May; Alwin D R Huitema; Remco de Bree
Journal:  J Clin Med       Date:  2020-11-23       Impact factor: 4.241

8.  Translating Evidence-Based Guidelines into Practice-Are We Getting It Right? A Multi-Centre Prospective International Audit of Nutrition Care in Patients with Foregut Tumors (INFORM).

Authors:  Merran Findlay; Judith D Bauer; Rupinder Dhaliwal; Marian de van der Schueren; Alessandro Laviano; Adrianne Widaman; Lisa Martin; Andrew G Day; Leah M Gramlich
Journal:  Nutrients       Date:  2020-12-11       Impact factor: 5.717

9.  Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors.

Authors:  Lorena Arribas; Maria Plana; Miren Taberna; Maria Sospedra; Noelia Vilariño; Marc Oliva; Natalia Pallarés; Ana Regina González Tampán; Luis Miguel Del Rio; Ricard Mesia; Vickie Baracos
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

10.  The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy.

Authors:  L F J Huiskamp; N Chargi; L A Devriese; P A de Jong; R de Bree
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-04-25       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.